p53 activity contributes to defective interfollicular epidermal differentiation in hyperproliferative murine skin

DOI: 10.1111/bjd.14048

Dear Editor, Skin diseases affect a significant percentage of the population and are often the result of a complex interplay between autoimmune dysregulation, and abnormal epidermal differentiation and proliferation. Origins may be genetic and/or environmental, and while no complete cure exists for conditions such as psoriasis, a range of treatments, including retinoids and antibodies against tumour necrosis factor-α and interleukin-17, have shown therapeutic efficacy, although relapses can occur. While there is no definitive mouse model for psoriasis, some do present with abnormal skin phenotypes that have revealed interesting molecular drivers. For example, agonist-treated peroxisome proliferator-activated receptor (PPAR) β/δ transgenic mice develop psoriasis-like conditions with failed compaction of the granular layer, which can be countered by PPARβ/δ antagonists. PPARβ/δ is also upregulated in human psoriasis and murine ichthyosis, but has proinflammatory, anti-inflammatory and prodifferentiation properties in various contexts. PPARγ, although predominantly expressed in the sebaceous gland, has similar prodifferentiation effects, and can reduce inflammation and promote barrier formation in mice with induced parakeratosis (Fig. S1; see Supporting Information).

The tumour suppressor p53 is upregulated in the pathogenesis of human chronic plaque-type psoriasis (Fig. 1a), and its role in skin disease has long been questioned. In additional animal studies, p53 has been found to be largely dispensable to epidermal homeostasis, with gene loss only causing minor alterations in murine catagen, and paradoxically, p53 deletion reduces oncogenesis in transgenic mouse skin carcinogenesis studies. p53 knockdown also promotes squamous differentiation in human keratinocytes cultured in vitro, which suggests p53 activation may impair keratinocyte differentiation in the interfollicular epidermis; however, this has not been tested in vivo.

A parakeratotic differentiation programme can be invoked by high MYC activity in keratinocytes; thus, K14MycER mice form a useful model of hyperproliferative skin. They overexpress MYC fused with the tamoxifen-responsive mutant oestrogen receptor ligand binding domain in the keratin 14 (K14)-positive basal layer of the epidermis and, upon activation with high-dose 4-hydroxytamoxifen (4OHT), exhibit parakeratotic lesions of acanthosis, hyperkeratosis and dermal inflammatory infiltration (see Fig. S1; see Supporting Information). Our K14MycER mice also show dose-dependent activation of the tumour suppressor p53 (Fig. 1b).

We previously crossed K14MycER mice with p53 knockout animals and demonstrated that aberrant p53 activity interferes with sebaceous gland differentiation by impairing androgen receptor function. In this study we investigated if p53 activity also contributes to defective interfollicular epidermal differentiation in the same cohort of animals. Full materials and methods are available in Appendix S1 (see Supporting Information). Our results show K14MycER p53null mice exhibited persistent hyperproliferation (Fig. S1; see Supporting Information).

Fig 1. Characterization of K14MycER p53null mouse epidermis. (a) Human scalp and psoriasis lesions immunostained for p53 (n = 6). (b) Mouse back skin from wild-type (WT), K14MycER (Myc-) and K14MycER p53 knockout (Myc: p53null) mice 4 days after treatment with 0-1 mg or 1-5 mg 4-hydroxytamoxifen as indicated, immunostained for p53 and counterstained with haematoxylin. (c) Mice treated as in (b), including p53 knockout (p53null) controls stained with haematoxylin and eosin (H&E). The granular layer was not visible in 21-39 ± 0.01% of K14MycER p53 wild-type (WT; p53wt) skin (as a proportion of length) and 22-64 ± 0.03% of K14MycER p53 heterozygous (p53het) skin. In contrast, the granular layer was only absent in 10-85 ± 0.03% of K14MycER p53null skin (*P < 0.05). (d) Mouse skin immunostained for keratin 6 (K6) and keratin 14 (K14), and counterstained with nuclear dye 4',6-diamidino-2-phenylindole (DAPI). (e) Mouse skin immunostained for K14, fatty acid binding protein 5 (FABP5) and DAPI, and (f) mouse skin immunostained for K14, loricrin (LOR) and DAPI. (g–n) Quantitative reverse transcription polymerase chain reaction for indicated mRNAs relative to Gapdh, standardized to WT mice (defined as 1). K14MycER (Myc-) mice shown by grey bars of p53wt, p53het and p53null status. (j) MYC activity alone induced downregulation of Krt10 mRNA, although (k) the K10 protein persists in this time frame and there is upregulation of Flg mRNA (Fig. S1; see Supporting Information). (l, m) Genes that showed MYC and p53-dependent regulation included If and Ppl, such that deletion of even one functional p53 allele resulted in a significant upregulation of mRNA (g, n). Most significantly, hyperproliferative Krt6a and Pparg/β/δ expression, which was upregulated in K14MycER p53wt/het mice, was reduced in K14MycER p53null mice. We have shown previously that K14MycER p53null mice have increased Pparg mRNA expression, and here demonstrate the increased peroxisome proliferator-activated receptor (PPAR) γ protein expression is predominantly in the sebaceous gland (Fig. S1; see Supporting Information). n = 3–5. Error bars represent SEM. *P < 0.01, **P < 0.005. Scale bars 50 μm. Rel. Exp., relative expression.
Fig 2. Retinoic acid signalling and p53. (a) Mouse telogen back skin [wild-type (WT:) and K14MycER (Myc:) mice] treated once with acetone or 1.5 mg 4-hydroxytamoxifen (4OHT) and daily with 0.016 mg BMS493 for 4 days, stained with haematoxylin and eosin (H&E) and (b) immunostained for p53 with haematoxylin counterstain. (c) Haematoxylin and eosin analysis of K14MycER (MycA:) mice treated with 1.5 mg 4OHT after 4 days. (d) p53 immunostaining of mice in (c) with haematoxylin counterstain. (e) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for p53 mRNA relative to Gapdh, standardized to wild-type (WT) mice (defined as 1). Mice (including transgenics and WT siblings) from the 206 p53 further upon deletion of binding protein 5 (FABP5) and DAPI, and (g) immunostained for K14, fatty acid binding protein 5 (FABP5) and DAPI, and (h) immunostained for K14, loricrin (LOR) and DAPI. (i) Immunostained for keratin 6 (K6), keratin 14 (K14) and 4',6-diamidino-2-phenylindole (DAPI), (g) immunostained for K14, fatty acid binding protein 5 (FABP5) and DAPI, and (h) immunostained for K14, loricrin (LOR) and DAPI. (i–l) qRT-PCR for indicated mRNAs relative to Gapdh, standardized to WT mice (defined as 1). Mice (including transgenics and WT siblings) from the K14MycER (Myc:) strain are shown by the grey bars and mice from the K14MycAER (MycA:) strains are shown by the grey bars. (f) Immunostained for keratin 6 (K6), keratin 14 (K14) and 4',6-diamidino-2-phenylindole (DAPI), (g) immunostained for K14, fatty acid binding protein 5 (FABP5) and DAPI, and (h) immunostained for K14, loricrin (LOR) and DAPI. (i–l) qRT-PCR for indicated mRNAs relative to Gapdh, standardized to WT mice (defined as 1). Mice (including transgenics and WT siblings) from the K14MycER (Myc:) strain are shown by the grey bars and mice from the K14MycAER (MycA:) strains are shown by the grey bars. (m) Summary of gene changes in transgenic mouse strains. (+) indicates gain, (−) indicates reduction, (o) indicates unchanged. Magnitude indicated by number of ± symbols. (o) Summary model of proposed signalling pathway (note that BMS493 and MYCA can inhibit retinoic acid receptor activity and prevent p53 activity). a = 3–9. Error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars = 50 μm. N/A, not applicable; Rel. Exp., relative expression; PPAR, peroxisome proliferator-activated receptor.
References


Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Appendix S1. Materials and methods.

Fig S1. Further characterization of K14MycER, K14MycER p53null and K14MycAER mouse epidermis.

Funding sources: This work was supported by Professor Fiona M. Watt via the Medical Research Council, Wellcome Trust, CRUK, EU FP7 programme, the University of Cambridge, and Hutchison Whampoa Ltd. This work was also supported by Associate Professor Ian M. Smyth and Monash University.

Conflicts of interest: none declared.